NASDAQ: JANX - Janux Therapeutics, Inc.

Rentabilidad a seis meses: +18.06%
Sector: Healthcare

Calendario de promoción Janux Therapeutics, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Más detalles
The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

Выручка 0.00038
EBITDA -0.0038
Число акций ао 0.04402 млрд
P/S 223.74
P/BV 2.22
EV/EBITDA -0.8876
Цена ао 55.95
ISIN US47103J1051
Сайт https://www.januxrx.com
Валюта usd
IPO date 2021-06-11
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Cambio de precio por día: -0.1606% (56.04)
Cambio de precio por semana.: +6.09% (52.74)
Cambio de precio por mes: +11.32% (50.26)
Cambio de precio en 3 meses.: +30.85% (42.76)
Cambio de precio en seis meses: +18.06% (47.39)
Cambio de precio por año: +802.42% (6.2)
Cambio de precio en 3 años.: +160.47% (21.48)
Cambio de precio desde principios de año.: +457.27% (10.04)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 56.85 1
P/BV 1.33 9
P/E 0 0
EV/EBITDA -6.55 0
Total: 3.75

Eficiencia

Nombre Significado Calificación
ROA, % -15.32 0
ROE, % -16.93 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.3455 10
Total: 8.8

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 2027.11 10
Rentabilidad Ebitda, % 1769.05 10
Rentabilidad EPS, % 100.51 10
Total: 10
Más detalles

Instituciones Volumen Compartir, %
RA Capital Management, L.P. 9165652 17.74
FMR, LLC 4671213 9.04
BVF Inc. 4579818 8.87
Orbimed Advisors LLC. 3317927 6.42
Citadel Advisors Llc 3120205 6.04
Janus Henderson Group PLC 1931477 3.74
Blackrock Inc. 1762101 3.41
Adage Capital Partners GP L.L.C. 1355475 2.62
Vanguard Group Inc 979483 1.9
Geode Capital Management, LLC 408190 0.79

ETF Compartir, % Rentabilidad del año, % Dividendos, %
Avantis U.S. Equity ETF 0.00103 32.224830464267 1.59151
Virtus LifeSci Biotech Clinical Trials ETF 0.93949 63.040315712071 0.33
ProShares Ultra Nasdaq Biotechnology 0.16649 51.697637072723 0.85651
Range Cancer Therapeutics ETF 1.74852 47.24446537918 0.11955
Dimensional US Core Equity Market ETF 0.00007 30.983243755928 1.40618
Dimensional U.S. Equity ETF 0.00061 31.530984204131 1.3557
iShares ESG Aware MSCI USA Small-Cap ETF 0.05375 33.616398243045 1.49366
Fidelity MSCI Health Care Index ETF 0.01547 13.390080209527 1.46057
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.0218 31.359936575053 1.41955
ProShares Hedge Replication ETF 0.0082 5.9237999659878 1.47892
Humankind US Stock ETF 0.01472 18.809430395549 1.99919
Invesco Nasdaq Biotechnology ETF 0.24933 28.578975171685 0.8565
iShares Russell 2000 Growth ETF 0.10435 38.042556988 0.6026
iShares Russell 3000 ETF 0.00313 32.57283798366 1.43482
Direxion Daily S&P Biotech Bull 3x Shares 0.31451 4067.9190751445 0.25924
SPDR Portfolio MSCI Global Stock Market ETF 0.00288 23.600605143722 2.19607
ProShares UltraPro Russell2000 0.0304 89.821266282945 1.47873
Vanguard U.S. Momentum Factor ETF 0.14 45.845704753962 1.05834
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.1 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0.05 35.648084105685 1.48801
Principal Healthcare Innovators ETF 0.25252 618.4964157054 0.8416
Future Tech ETF 0.25252 426.33969118983 0.8416



Supervisor Título profesional Pago año de nacimiento
Dr. David Alan Campbell Ph.D. President, CEO & Director 1.04M 1960 (64 año)
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 723k 1965 (59 años)
Mr. Charles M. Winter Chief Technical Officer 590.4k 1969 (55 años)
Mr. James Pennington General Counsel N/A
Ms. Brenda Van Vreeswyk Head of Human Resources N/A
Mr. Andy Hollman Meyer Chief Business Officer N/A 1984 (40 años)
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer N/A 1986 (38 años)
Mr. Matt Whitmire Vice President of Finance
Ms. Maria Dobek Principal Accounting Officer & VP of Accounting 1989 (35 años)

DIRECCIÓN: United States, La Jolla. CA, 11099 North Torrey Pines Road - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.januxrx.com